The Experts below are selected from a list of 1215054 Experts worldwide ranked by ideXlab platform

Great Western Sugar Company Institution - One of the best experts on this subject based on the ideXlab platform.

Francisco J Fraga - One of the best experts on this subject based on the ideXlab platform.

  • early diagnosis of alzheimer s disease the role of biomarkers including advanced eeg signal Analysis Report from the ifcn sponsored panel of experts
    Clinical Neurophysiology, 2020
    Co-Authors: P M Rossini, R Di Iorio, F Vecchio, Maria Anfossi, Claudio Babiloni, Marco Bozzali, Amalia C Bruni, Stefano F Cappa, Javier Escudero, Francisco J Fraga
    Abstract:

    Alzheimer's disease (AD) is the most common neurodegenerative disease among the elderly with a progressive decline in cognitive function significantly affecting quality of life. Both the prevalence and emotional and financial burdens of AD on patients, their families, and society are predicted to grow significantly in the near future, due to a prolongation of the lifespan. Several lines of evidence suggest that modifications of risk-enhancing life styles and initiation of pharmacological and non-pharmacological treatments in the early stage of disease, although not able to modify its course, helps to maintain personal autonomy in daily activities and significantly reduces the total costs of disease management. Moreover, many clinical trials with potentially disease-modifying drugs are devoted to prodromal stages of AD. Thus, the identification of markers of conversion from prodromal form to clinically AD may be crucial for developing strategies of early interventions. The current available markers, including volumetric magnetic resonance imaging (MRI), positron emission tomography (PET), and cerebral spinal fluid (CSF) Analysis are expensive, poorly available in community health facilities, and relatively invasive. Taking into account its low cost, widespread availability and non-invasiveness, electroencephalography (EEG) would represent a candidate for tracking the prodromal phases of cognitive decline in routine clinical settings eventually in combination with other markers. In this scenario, the present paper provides an overview of epidemiology, genetic risk factors, neuropsychological, fluid and neuroimaging biomarkers in AD and describes the potential role of EEG in AD investigation, trying in particular to point out whether advanced Analysis of EEG rhythms exploring brain function has sufficient specificity/sensitivity/accuracy for the early diagnosis of AD.

Paul Trueman - One of the best experts on this subject based on the ideXlab platform.

  • principles of good practice for budget impact Analysis Report of the ispor task force on good research practices budget impact Analysis
    Value in Health, 2007
    Co-Authors: Josephine Mauskopf, Sean D Sullivan, L Annemans, Jaime J Caro, Daniel C Mullins, Mark Nuijten, Ewa Orlewska, John B Watkins, Paul Trueman
    Abstract:

    Objectives: There is growing recognition that a comprehensive economic assessment of a new health-care intervention at the time of launch requires both a cost-effectiveness Analysis (CEA) and a budget impact Analysis (BIA). National regulatory agencies such as the National Institute for Health and Clinical Excellence in England and Wales and the Pharmaceutical Benefits Advisory Committee in Australia, as well as managed care organizations in the United States, now require that companies submit estimates of both the costeffectiveness and the likely impact of the new health-care interventions on national, regional, or local health plan budgets. Although standard methods for performing and presenting the results of CEAs are well accepted, the same progress has not been made for BIAs. The objective of this Report is to present guidance on methodologies for those undertaking such analyses or for those reviewing the results of such analyses. Methods: The Task Force was appointed with the advice and consent of the Board of Directors of ISPOR. Members were experienced developers or users of budget impact models, worked in academia, industry, and as advisors to governments, and came from several countries in North America, Oceana, Asia, and Europe. The Task Force met to develop core assumptions and an outline before preparing a draft Report. They solicited comments on the outline and two drafts from a core group of external reviewers and more broadly from the membership of ISPOR at two ISPOR meetings and via the ISPOR web site. Results: The Task Force recommends that the budget impact of a new health technology should consider the perspective of the specific health-care decision-maker. As such, the BIA should be performed using data that reflect, for a specific health condition, the size and characteristics of the population, the current and new treatment mix, the efficacy and safety of the new and current treatments, and the resource use and costs for the treatments and symptoms as would apply to the population of interest. The Task Force recommends that budget impact analyses be generated as a series of scenario analyses in the same manner that sensitivity analyses would be provided for CEAs. In particular, the input values for the calculation and the specific cost outcomes presented (a scenario) should be specific to a particular decision-maker’s population and information needs. Sensitivity Analysis should also be in the form of alternative scenarios chosen from the perspective of the decision-maker. The primary data sources for estimating the budget impact should be published clinical trial estimates and comparator studies for efficacy and safety of current and new technologies as well as, where possible, the decision-maker’s own population for the other parameter estimates. Suggested default data sources also are recommended. These include the use of published data, well-recognized local or national statistical information and in special circumstances, expert opinion. Finally, the Task Force recommends that the analyst use the simplest design that will generate credible and transparent estimates. If a health condition model is needed for the BIA, it should reflect health outcomes and their related costs in the total affected population for each year after the new intervention is introduced into clinical practice. The model should be consistent with that used for the CEA with regard to clinical and economic assumptions. Conclusions: The BIA is important, along with the CEA, as part of a comprehensive economic evaluation of a new health technology. We propose a framework for creating budget impact models, guidance about the acquisition and use of data to make budget projections and a common Reporting format that will promote standardization and transparency. Adherence to these proposed good research practice principles would not necessarily supersede jurisdiction-specific budget impact guidelines, but may support and enhance local

Jalil Jafari - One of the best experts on this subject based on the ideXlab platform.

  • loss of coolant accident analyses on tehran research reactor by relap5 mod3 2 code
    Progress in Nuclear Energy, 2007
    Co-Authors: Afshin Hedayat, H Davilu, Jalil Jafari
    Abstract:

    In this paper, a loss of coolant accident (LOCA) in Tehran research reactor (TRR) is analyzed. The following procedure consists of three major parts. First, a RELAP5 nodalization of the core and the most important components of the primarily cooling system are developed and steady state condition is simulated and compared with experimental data [SAR for TRR, October 2002. Safety Analysis Report for Tehran research reactor. Nuclear Research Center of the Atomic Energy Organization of Iran, Tehran] to validate the nodalization. Then, two large break points are selected for design basis accident analyses. Finally, two main loss of coolant accidents are simulated and developed to analyze LOCA in TRR. It can be concluded that TRR is safe against the LOCA. And also RELAP5/MOD3.2 code can simulate research reactors at operating conditions well but it seems that this code cannot simulates large transient phases of the research reactors accurately as steady state condition specially in low pressure two phase mixtures (water and air).

P M Rossini - One of the best experts on this subject based on the ideXlab platform.

  • early diagnosis of alzheimer s disease the role of biomarkers including advanced eeg signal Analysis Report from the ifcn sponsored panel of experts
    Clinical Neurophysiology, 2020
    Co-Authors: P M Rossini, R Di Iorio, F Vecchio, Maria Anfossi, Claudio Babiloni, Marco Bozzali, Amalia C Bruni, Stefano F Cappa, Javier Escudero, Francisco J Fraga
    Abstract:

    Alzheimer's disease (AD) is the most common neurodegenerative disease among the elderly with a progressive decline in cognitive function significantly affecting quality of life. Both the prevalence and emotional and financial burdens of AD on patients, their families, and society are predicted to grow significantly in the near future, due to a prolongation of the lifespan. Several lines of evidence suggest that modifications of risk-enhancing life styles and initiation of pharmacological and non-pharmacological treatments in the early stage of disease, although not able to modify its course, helps to maintain personal autonomy in daily activities and significantly reduces the total costs of disease management. Moreover, many clinical trials with potentially disease-modifying drugs are devoted to prodromal stages of AD. Thus, the identification of markers of conversion from prodromal form to clinically AD may be crucial for developing strategies of early interventions. The current available markers, including volumetric magnetic resonance imaging (MRI), positron emission tomography (PET), and cerebral spinal fluid (CSF) Analysis are expensive, poorly available in community health facilities, and relatively invasive. Taking into account its low cost, widespread availability and non-invasiveness, electroencephalography (EEG) would represent a candidate for tracking the prodromal phases of cognitive decline in routine clinical settings eventually in combination with other markers. In this scenario, the present paper provides an overview of epidemiology, genetic risk factors, neuropsychological, fluid and neuroimaging biomarkers in AD and describes the potential role of EEG in AD investigation, trying in particular to point out whether advanced Analysis of EEG rhythms exploring brain function has sufficient specificity/sensitivity/accuracy for the early diagnosis of AD.